PMID: 2126437Nov 1, 1990Paper

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

Atherosclerosis
D HunninghakeW Insull

Abstract

This multicenter, double-blind, placebo-controlled, dose-response study was conducted in patients with primary hypercholesterolemia to examine the effects of pravastatin, a selective inhibitor of HMG-CoA reductase, on plasma lipids and lipoproteins. A total of 306 patients on cholesterol-lowering diets received twice daily doses of 5 mg, 10 mg, 20 mg pravastatin, or placebo for 12 weeks. Marked reductions in low density lipoprotein (LDL) cholesterol and total cholesterol were observed after 1 week of treatment; maximum lipid-lowering effects occurred at 4 weeks and were sustained for the duration of the trial. At week 12, pravastatin treatment resulted in dose-dependent mean reductions from baseline in LDL cholesterol of 17.5%, 22.9%, and 30.8% for the 3 doses tested (P less than or equal to 0001 compared with baseline and placebo). The reduction in LDL cholesterol was log-linear with respect to dose; each doubling of dose reduced LDL cholesterol an additional 6.5%. Dose-dependent reductions in total cholesterol from 12.9% to 23.3% also occurred (P less than or equal to 0.001). Triglycerides decreased by as 15.4% (P less than or equal to 0.001) and high-density lipoprotein (HDL) cholesterol increased approximately 7% (P less th...Continue Reading

References

Dec 1, 1987·Controlled Clinical Trials·D H BlankenhornR H Selzer
Jun 27, 1986·The American Journal of Cardiology·D W Bilheimer
Jul 1, 1984·Progress in Cardiovascular Diseases·W V BrownH N Ginsberg
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S M Grundy, D W Bilheimer
Nov 1, 1984·Scientific American·M S Brown, J L Goldstein
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein

❮ Previous
Next ❯

Citations

Oct 1, 1994·Clinical Cardiology·P T Kuo
Jun 1, 1993·Journal of Clinical Pharmacology·D B HunninghakeM J Mellies
Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Jun 1, 1993·Atherosclerosis·M J MelliesH Y Pan
Mar 8, 2005·Survey of Ophthalmology·Robyn Heather GuymerPaul Nigel Baird
Mar 21, 1998·Journal of the American College of Cardiology·J K WilliamsP Libby
Sep 1, 1993·British Journal of Clinical Pharmacology·J TriscariH Y Pan
Jun 10, 2010·Diabetology & Metabolic Syndrome·Ana-Lucia A KaterSandra Rg Ferreira
May 26, 1994·The American Journal of Cardiology·L A Jokubaitis
Aug 26, 1998·The Tohoku Journal of Experimental Medicine·T SatoM Fukuda
Feb 1, 1992·Journal of Clinical Pharmacology·C E HalstensonH Pan
Aug 1, 1993·Australian and New Zealand Journal of Medicine·C J LintottJ Bremer
Jun 28, 2001·Journal of Atherosclerosis and Thrombosis·T NagaiM Mori
Nov 2, 1992·The Medical Journal of Australia·L A SimonsA Parfitt
Sep 1, 1992·Current Problems in Cardiology·J S Prihoda, D R Illingworth

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.